Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 10:57 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 52 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: daptomycin Clear all
Completed Phase 4 Interventional Results available

Safety and Efficacy Study of Daptomycin in Pediatric Participants (1 to 17 Years-old) With Skin and Skin Structure Infections

NCT00711802
View directory record Official record
Conditions
Skin Diseases, Infectious
Interventions
Daptomycin, Standard of Care (SOC)
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
1 Year to 17 Years
Enrollment
396 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
22
States / cities
Birmingham, Alabama • Oakland, California • Orange, California + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2018 · Synced Oct 19, 2026, 10:57 AM EDT
Terminated Phase 4 Interventional

Daptomycin Use for Antimicrobial Prophylaxis in Methicillin Resistant Staphylococcus Aureus (MRSA) Colonized Adult Patients Undergoing Primary Elective Hip, Knee, or Shoulder Arthroplasty

NCT01196169
View directory record Official record
Conditions
Staphylococcal Infections, Methicillin-resistant Staphylococcus Aureus
Interventions
Daptomycin, Vancomycin
Drug
Lead sponsor
Mountain Home Research & Education Corporation
Other
Eligibility
18 Years to 90 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
2
States / cities
Johnson City, Tennessee • Mountain Home, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 3, 2014 · Synced Oct 19, 2026, 10:57 AM EDT
Withdrawn Not applicable Interventional

Daptomycin or Vancomycin in Treating Bacteria in the Blood in Patients With Neutropenia Caused By Chemotherapy

NCT00296049
View directory record Official record
Conditions
Infection, Neutropenia, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
daptomycin, vancomycin
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
Up to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 10, 2018 · Synced Oct 19, 2026, 10:57 AM EDT
Terminated Phase 4 Interventional Results available

A Pilot Study of Daptomycin for Antimicrobial Prophylaxis

NCT00572260
View directory record Official record
Conditions
Antimicrobial Prophylaxis
Interventions
daptomycin 6 mg/kg IV
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 25, 2014 · Synced Oct 19, 2026, 10:57 AM EDT
Completed Not applicable Interventional Results available

Daptomycin for the Treatment of Severe Necrotizing Soft-Tissue Infections

NCT00261807
View directory record Official record
Conditions
Fasciitis, Necrotizing, Severe Necrotizing Skin and Soft Tissue Infections, Fournier's Gangrene
Interventions
Daptomycin 6mg/kg/day
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 27, 2022 · Synced Oct 19, 2026, 10:57 AM EDT
Completed Phase 2 Interventional Results available

Catheter Related - Gram Positive Bloodstream Infections

NCT00467272
View directory record Official record
Conditions
Bloodstream Infection
Interventions
Daptomycin
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 8, 2021 · Synced Oct 19, 2026, 10:57 AM EDT
Completed Phase 2 Interventional Results available

Study of Daptomycin in Subjects Undergoing Surgery for Osteomyelitis Associated With an Infected Prosthetic Caused by Staphylococci

NCT00428844
View directory record Official record
Conditions
Osteomyelitis
Interventions
daptomycin, vancomycin, teicoplanin, nafcillin, oxacillin, flucloxacillin
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 80 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
17
States / cities
Little Rock, Arkansas • Englewood, Colorado • Washington D.C., District of Columbia + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2018 · Synced Oct 19, 2026, 10:57 AM EDT
Terminated Phase 3 Interventional Results available

Daptomycin Versus Placebo in Patients With Neutropenia and Fever

NCT01216241
View directory record Official record
Conditions
Febrile Neutropenia
Interventions
Daptomycin, Saline Placebo
Drug · Other
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Apr 10, 2014 · Synced Oct 19, 2026, 10:57 AM EDT
Completed Phase 4 Interventional

Dalbavancin For The Treatment of Gram Positive Osteoarticular Infections

NCT03426761
View directory record Official record
Conditions
Bone Infection, Osteomyelitis, Septic Arthritis, Joint Infection, Prosthetic Joint Infection
Interventions
Dalbavancin, Vancomycin
Drug
Lead sponsor
Infectious Diseases Physicians, Inc.
Other
Eligibility
18 Years to 80 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Annandale, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 3, 2023 · Synced Oct 19, 2026, 10:57 AM EDT
Completed Phase 2 Interventional Results available

Daptomycin in Treating Neutropenia and Fever in Patients With Cancer

NCT00335478
View directory record Official record
Conditions
Fever, Sweating, Hot Flashes, Infection, Neutropenia, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
Daptomycin
Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years to 99 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Oct 19, 2026, 10:57 AM EDT
Terminated Phase 3 Interventional Results available

A Phase 3 Telavancin Staphylococcus Aureus (S. Aureus) Bacteremia Trial

NCT02208063
View directory record Official record
Conditions
Bacteremia
Interventions
Telavancin, Vancomycin, Daptomycin, Synthetic penicillin, Cefazolin
Drug
Lead sponsor
Cumberland Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 17, 2020 · Synced Oct 19, 2026, 10:57 AM EDT
Terminated Phase 4 Interventional Results available

Postoperative Antibiotic Management Duration Following Surgery for Intravenous Drug Abuse (IVDA) Endocarditis (OPTIMAL)

NCT05156437
View directory record Official record
Conditions
Endocarditis
Interventions
Amoxycillin, Cefalexin, Dicloxacillin, Linezolid, Levofloxacin, Rifampicin, Ampicillin, Oxacillin, Vancomycin, Daptomycin, Ceftriaxone, Cefepime, Ceftaroline
Drug
Lead sponsor
West Virginia University
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 19, 2026, 10:57 AM EDT
Terminated Phase 4 Interventional

Daptomycin in the Treatment of Patients With Renal Insufficiency and Complicated Skin and Skin Structure Infections

NCT00102947
View directory record Official record
Conditions
Soft Tissue Infections
Interventions
daptomycin (up to 14 days)
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
12
States / cities
Torrance, California • Tampa, Florida • Augusta, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2016 · Synced Oct 19, 2026, 10:57 AM EDT
Completed Phase 1 Interventional Results available

An Open Label Study to Describe the Pharmacokinetics of Daptomycin in Infants

NCT00942149
View directory record Official record
Conditions
Sepsis
Interventions
Daptomycin
Drug
Lead sponsor
Duke University
Other
Eligibility
48 Hours to 120 Days
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 15, 2013 · Synced Oct 19, 2026, 10:57 AM EDT
Completed Phase 4 Interventional

Safety and Efficacy Study of Ceftaroline in Subjects With Staphylococcus Aureus Bacteremia or With Persistent Methicillin-Resistant Staphylococcus Aureus Bacteremia

NCT01701219
View directory record Official record
Conditions
Staphylococcus Aureus Bacteremia, Methicillin-resistant Staphylococcus Aureus (MRSA) Bacteremia
Interventions
Ceftaroline fosamil
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
27
States / cities
Birmingham, Alabama • Sacramento, California • San Francisco, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2014 · Synced Oct 19, 2026, 10:57 AM EDT
Recruiting Phase 4 Interventional

Combination Antibiotic Therapy for Staphylococcus Aureus Bacteremia

NCT07376889
View directory record Official record
Conditions
Staphylococcus Aureus Bacteremia
Interventions
Antibiotic Monotherapy (AM) for patients with methicillin-sensitive S. aureus bacteremia (MSSAB), Antibiotic Monotherapy (AM) for patients with methicillin-resistant S. aureus bacteremia (MRSAB), Combination Antibiotic Therapy (CAT) for patients with methicillin-sensitive S. aureus bacteremia (MSSAB), Combination Antibiotic Therapy (CAT) for patients with methicillin-resistant S. aureus bacteremia (MRSAB)
Drug
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
18 Years and older
Enrollment
2,096 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
13
States / cities
Brighton, Colorado • Denver, Colorado • Grand Junction, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 19, 2026, 10:57 AM EDT
Completed Phase 4 Interventional Results available

Daptomycin Versus Vancomycin in Participants With Skin Infections Due to MRSA

NCT01419184
View directory record Official record
Conditions
Staphylococcal Skin Infections
Interventions
Daptomycin, Vancomycin
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
25
States / cities
Mobile, Alabama • Chula Vista, California • Escondido, California + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2018 · Synced Oct 19, 2026, 10:57 AM EDT
Terminated Phase 4 Interventional Results available

Comparing Oral Versus Parenteral Antimicrobial Therapy

NCT05977868
View directory record Official record
Conditions
Endovascular Infection, Bone and Joint Infection, Skin and Soft Tissue Infection, Pulmonary Infection, Gastrointestinal Infection, Genitourinary Infection
Interventions
Amoxicillin, amoxicillin-clavulanate, cefadroxil, cefpodoxime, cefalexin, ciprofloxacin, delafloxacin, doxycycline, levofloxacin, linezolid, Ampicillin, ampicillin-sulbactam, cefazolin, cefepime, ceftaroline, ceftazidime, ceftazidime-avibactam, dalbavancin, daptomycin, ertapenem
Drug
Lead sponsor
West Virginia University
Other
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Aug 26, 2025 · Synced Oct 19, 2026, 10:57 AM EDT
Completed Phase 1 Interventional Results available

Study to Evaluate Daptomycin Given During Dialysis and After Dialysis

NCT00882557
View directory record Official record
Conditions
End-stage Renal Disease, Renal Failure Chronic Requiring Hemodialysis
Interventions
daptomycin
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
2
States / cities
Cypress, California • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 6, 2018 · Synced Oct 19, 2026, 10:57 AM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Vascular Surgical Antibiotic Prophylaxis Study (VSAPS 2)

NCT01612052
View directory record Official record
Conditions
MRSA - Methicillin Resistant Staphylococcus Aureus Infection
Interventions
Antibiotic Prophylaxis
Drug
Lead sponsor
CAMC Health System
Other
Eligibility
18 Years to 80 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Charleston, West Virginia
Source: ClinicalTrials.gov public record
Updated Feb 20, 2013 · Synced Oct 19, 2026, 10:57 AM EDT
Terminated Phase 2 Interventional Results available

Efficacy of Oral Antibiotic Therapy Compared to Intravenous Antibiotic Therapy for Osteomyelitis

NCT02168816
View directory record Official record
Conditions
Osteomyelitis
Interventions
Intravenous Antibacterial Agent, Oral Antibacterial Agent
Drug
Lead sponsor
Loyola University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 19, 2018 · Synced Oct 19, 2026, 10:57 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Vancomycin and Daptomycin Plus Cefazolin for Preoperative Vascular Surgery Prophylaxis

NCT00967941
View directory record Official record
Conditions
MRSA Infections
Interventions
Not listed
Lead sponsor
CAMC Health System
Other
Eligibility
18 Years to 90 Years
Enrollment
169 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
1
States / cities
Charleston, West Virginia
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 19, 2026, 10:57 AM EDT
Completed Phase 2 Interventional Results available

DOTS: Dalbavancin as an Option for Treatment of Staphylococcus Aureus Bacteremia

NCT04775953
View directory record Official record
Conditions
Staphylococcal Bacteraemia
Interventions
Cefazolin, Dalbavancin, Daptomycin, Nafcillin, Oxacillin, Vancomycin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
23
States / cities
Birmingham, Alabama • Sacramento, California • Torrance, California + 19 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2024 · Synced Oct 19, 2026, 10:57 AM EDT
Terminated Not applicable Interventional Results available

Cerebrospinal Fluid Pharmacokinetics of Daptomycin

NCT01025271
View directory record Official record
Conditions
Meningitis
Interventions
Daptomycin
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 12, 2013 · Synced Oct 19, 2026, 10:57 AM EDT